Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUKE P DREISBACH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1831109792
CMS profile
37730
Location
RANCHO MIRAGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,207.62

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,207.62 172

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUKE P DREISBACH

NPI 1831109792 · CMS profile ID 37730

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

RANCHO MIRAGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831109792?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUKE P DREISBACH, NPI 1831109792, CMS profile ID 37730. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831109792?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LUKE P DREISBACH, NPI 1831109792, CMS profile ID 37730. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831109792?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LUKE P DREISBACH, NPI 1831109792, CMS profile ID 37730, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1831109792?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $3,207.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $19.1105/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609327 CMS
Janssen Biotech, Inc. $9.6605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885573169 CMS
Merck Sharp & Dohme LLC $24.9805/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944771707 CMS
Kite Pharma, Inc. $15.5605/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920057935 CMS
Novartis Pharmaceuticals Corporation $18.1305/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609317 CMS
GlaxoSmithKline, LLC. $22.1105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944640101 CMS
Seagen Inc. $15.8705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904083587 CMS
AVEO Pharmaceuticals, Inc. $24.3405/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950105301 CMS
Regeneron Healthcare Solutions, Inc. $19.7404/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927153667 CMS
Adaptive Biotechnologies Corporation $27.1604/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951437201 CMS
PUMA BIOTECHNOLOGY, INC. $27.3604/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942288545 CMS
Novartis Pharmaceuticals Corporation $16.6504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609313 CMS
Pharmacyclics LLC, an AbbVie Company $19.6804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890339557 CMS
EISAI INC. $24.3404/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908058805 CMS
Novartis Pharmaceuticals Corporation $15.8204/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609315 CMS
E.R. Squibb & Sons, L.L.C. $22.4404/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932792653 CMS
Ipsen Biopharmaceuticals, Inc $21.1404/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893406943 CMS
Novartis Pharmaceuticals Corporation $9.4504/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609309 CMS
TOLMAR Pharmaceuticals, Inc. $24.5104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954443851 CMS
Merck Sharp & Dohme LLC $11.7004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944785009 CMS
Incyte Corporation $18.8604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943011751 CMS
Novartis Pharmaceuticals Corporation $14.6004/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609311 CMS
MorphoSys, US Inc. $27.7404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962537953 CMS
Pharmacyclics LLC, an AbbVie Company $22.2904/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890339555 CMS
Astellas Pharma US Inc $9.3903/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940158575 CMS
Novartis Pharmaceuticals Corporation $18.4203/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609305 CMS
Novartis Pharmaceuticals Corporation $22.7603/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609303 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.1103/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955626773 CMS
Amgen Inc. $19.3603/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939785803 CMS
E.R. Squibb & Sons, L.L.C. $15.8403/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932792645 CMS
Janssen Biotech, Inc. $19.1203/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885573173 CMS
Janssen Biotech, Inc. $11.9503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885573177 CMS
Genentech USA, Inc. $13.8803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950793809 CMS
Lilly USA, LLC $12.8503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918139223 CMS
Novartis Pharmaceuticals Corporation $16.2203/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609307 CMS
GlaxoSmithKline, LLC. $21.1403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944640089 CMS
ARRAY BIOPHARMA INC $4.5603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949537135 CMS
Deciphera Pharmaceuticals Inc. $13.5303/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953434241 CMS
Novartis Pharmaceuticals Corporation $13.0803/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609301 CMS
PFIZER INC. $21.9003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949515135 CMS
E.R. Squibb & Sons, L.L.C. $9.7303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932792643 CMS
Sobi, Inc $22.3003/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940369801 CMS
E.R. Squibb & Sons, L.L.C. $21.9502/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932792641 CMS
Incyte Corporation $15.6302/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943011743 CMS
PFIZER INC. $24.3702/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949553799 CMS
Novartis Pharmaceuticals Corporation $14.1002/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893609297 CMS
AstraZeneca Pharmaceuticals LP $16.9702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914628849 CMS
Daiichi Sankyo Inc. $21.9002/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930804311 CMS
Coherus Biosciences Inc. $19.0502/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956566345 CMS
Janssen Biotech, Inc. $18.8702/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885573153 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,535.91 164
PY2020 $2,278.93 133
PY2021 $2,677.78 144
PY2022 $3,207.62 172
PY2023 $3,389.98 157
PY2024 $3,607.64 170
PY2025 $4,117.11 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $22,955.03 6
PY2024 Recipient $930.72 4
PY2024 Principal investigator $6,618.60 1
PY2023 Recipient $924.11 2
PY2023 Principal investigator $22,691.70 2
PY2022 Principal investigator $319,932.35 5
PY2021 Principal investigator $2,336.00 2
PY2020 Principal investigator $17,811.99 10
PY2019 Principal investigator $90,131.82 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

6 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,000.00 11/27/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184266463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,548.00 11/27/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184266465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,517.00 11/27/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184266467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,891.00 11/27/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184266469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,184.00 11/27/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184266471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,815.03 06/05/2025 Non-covered Recipient Entity
DESERT HEMATOLOGY ONCOLOGY MEDICAL GROUP INC
A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184204205